Status:
COMPLETED
Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation
Lead Sponsor:
Pfizer
Conditions:
Ejaculation
Eligibility:
MALE
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
To determine whether UK-390,957 is an effective and safe treatment for premature ejaculation.
Eligibility Criteria
Inclusion
- Premature ejaculation as defined by DSM-IV
Exclusion
- History of erectile dysfunction
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
End Date :
June 1 2005
Estimated Enrollment :
460 Patients enrolled
Trial Details
Trial ID
NCT00143117
Start Date
August 1 2004
End Date
June 1 2005
Last Update
November 7 2012
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Tucson, Arizona, United States
2
Pfizer Investigational Site
Anaheim, California, United States
3
Pfizer Investigational Site
Atherton, California, United States
4
Pfizer Investigational Site
Beverly Hills, California, United States